...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of infection and chemotherapy: official journal of the Japan Society of Chemotherapy >Long-term successful control of super-multidrug-resistant human immunodeficiency virus type 1 infection by a novel combination therapy of raltegravir, etravirine, and boosted-darunavir.
【24h】

Long-term successful control of super-multidrug-resistant human immunodeficiency virus type 1 infection by a novel combination therapy of raltegravir, etravirine, and boosted-darunavir.

机译：通过拉格列韦，依曲韦林和加强型darunavir的新型联合疗法，长期成功地控制了耐多药耐药的人类免疫缺陷病毒1型感染。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Drug-resistant virus infection has been a major hurdle in the management of human immunodeficiency virus type 1 (HIV-1) infection. Recently, three novel antiretrovirals [raltegravir (RAL), etravirine (ETR), and darunavir (DRV)] were introduced into the market almost simultaneously, and salvage regimens containing these three antiretrovirals have been reported to exhibit strong potency against drug-resistant HIV-1 infection. However, the sustainability of such regimens remains unclear, particularly for patients infected with multidrug-resistant viruses. Here we report a case of super-multidrug-resistant HIV-1 infection which has been successfully controlled by novel combination therapy including RAL, ETR, and DRV for over 2 years, indicating that the novel combination could become an ultimate weapon against drug-resistant HIV infection and could alter the landscape of HIV salvage therapy.
机译：耐药病毒感染已成为管理人类1型免疫缺陷病毒（HIV-1）感染的主要障碍。最近，几乎同时将三种新型抗逆转录病毒药物[raltegravir（RAL），etravirine（ETR）和darunavir（DRV）]推向市场，据报道，包含这三种抗逆转录病毒药物的抢救方案对耐药HIV- 1感染。但是，这种方案的可持续性仍然不清楚，尤其是对于感染了多药耐药性病毒的患者。在这里，我们报告了一例超级耐多药的HIV-1感染病例，该病已通过包括RAL，ETR和DRV在内的新型联合疗法成功控制了2年多，这表明该新型组合可能成为抵抗耐药性的最终武器HIV感染并可能改变HIV挽救疗法的面貌。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号